Advertisement

Picture EBD Group BioTech Showcase 2021 Whitepaper Presenting 650x80
Organisation › Details

Immunocore Ltd.

Immunocore is one of the world’s leading biotechnology companies, with a highly innovative immuno-oncology platform technology called ImmTACs. ImmTACs are a novel class of biologic drugs based on the Company’s proprietary T cell receptor (TCR) technology which have the potential to treat diseases with high unmet medical need including cancer, infectious diseases and autoimmune diseases. Immunocore has a pipeline of wholly-owned and partnered ImmTAC programmes with robust clinical data. In addition to oncology, Immunocore is also developing programmes with its TCR-based platform as potential therapy for HIV and other infectious diseases. Immunocore aims to leverage the utility of its platform across a wide range of indications. Immunocore’s world-leading science and strong IP position has attracted major pharmaceutical companies including Genentech, GlaxoSmithKline, MedImmune, the biologics division of AstraZeneca, via discovery collaborations, as well as a co-discovery and co-development partnership with Lilly. The Company has also entered into combination trials with its lead programme, IMCgp100 in metastatic melanoma, with MedImmune and Lilly. Founded in 2008 from academic research originating at Oxford University, Immunocore is headquartered outside Oxford with US offices outside Philadelphia, Immunocore now has close to 280 staff. Immunocore’s current investors are well-renowned, leading international institutions including Woodford Investment Management, Malin Corporation, Eli Lilly and Company, RTW Investments, Fidelity Management & Research Company as well as other private shareholders. *

 

Period Start 2008-10-01 splitoff
  Group Immunocore (Group)
  Predecessor Medigene Ltd.
Products Industry ImmTAC technology
  Industry 2 tebentafusp (IMCgp100)
Persons Person Forster, Eliot (F-Star 201810– CEO before Immunocore + Creabilis + Solace Pharmaceuticals + Pfizer + GSK)
  Person 2 Fry, Paul (Vectura 202010 CFO before Immunocore + Vodafone + GSK)
     
Region Region Abingdon, Oxfordshire
  Country United Kingdom (GB)
  Street 101 Park Drive
Milton Park
  City OX14 4RX Abingdon, Oxfordshire
  Tel +44-1235-438600
    Address record changed: 2020-12-02
     
Basic data Employees D: 101 to 500 (2016-10-12)
     
    * Document for �About Section�: Immunocore Ltd.. (10/12/16). "Press Release: Immunocore Appoints Paul Fry as Chief Financial Officer". Oxford.
     
   
Record changed: 2020-09-26

Advertisement

Picture ConsulTech GmbH GDPR-compliant E-Col Cloud Document Management 650x80px

More documents for Immunocore (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture EBD Group BioTech Showcase 2021 Digital Event BTS2021 651x81




» top